Omyapharm FCC

A new generation of multifunctional mineral excipient
Omyapharm FCC

A new generation of multifunctional mineral excipient

- Innovative functionalized excipient for pharmaceuticals
- High efficiency carrier for multiple substances
- Controlled-release properties

Discover the benefits of Omyapharm FCC in your application.

Advantages

- High loading capability
- Controlled release vector
- Direct compressibility
- Stabilization of API's
- Dissolution enhancement

Particle size distribution (laser diffraction)  

Pore Size (mercury porosimeter)

- Size range 2.5 to 10 µm
- Highly porous nature
- Surface area range 30-70m²g⁻¹
Omyapharm FCC was granulated both by high shear mixer (HSM) and roller compaction (RC), with and without binder respectively. Granulation of Omyapharm FCC had no significant influence on tensile strength and porosity (figure A).

Also formulations with Omyapharm FCC showed higher porosity than formulations with MCC at different compression pressures (figure A).

Omyapharm FCC required comparable or lower compression pressures than other excipients such as MCC or mannitol, in order to produce robust tablets (figure B).

High porosity and tensile strength were preserved after blending Omyapharm FCC with an API like paracetamol (figures C and D).
Omyapharm FCC and Drug Loading

Preisig et al. (2014) European Journal of Pharmaceutics and Biopharmaceutics 87:548-558

Omyapharm FCC microparticles and four separate drugs with different permeability and solubility properties respectively were selected as model substances to investigate drug loading by solvent evaporation.

Nifedipine and Metronidazole benzoate loaded Omyapharm FCC: complete drug dissolution occurred in half the time.

Ibuprofen loaded Omyapharm FCC: little changes in dissolution rate were observed but proved to be an interesting alternative to micronization of this poorly soluble drug.

Losartan potassium loaded Omyapharm FCC: little changes in dissolution rate were observed but might be an advantage when low doses have to be administered.
ODTs are an alternative dosage form for patients who experience difficulty in swallowing, such as elderly and long term care patients as well as children.

Disintegration capacity of ODTs prepared by direct compression depends on tablet size and hardness. The harder the tablet the longer the disintegration time. ODTs formulated with Omyapharm FCC can be designed to have sufficient mechanical strength and disintegrate fast.
FDDS float in the stomach while releasing the drug they carry, due to their lower density compared to the gastric fluids. Thus, FDDS improve bioavailability of drugs whose site of action or absorption is located in the stomach or upper intestinal tract by increasing the gastric residence time. Given the low densities of Omyapharm FCC-based tablets, Omyapharm FCC is a promising novel pharmaceutical excipient for the preparation of FDDS.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Omyapharm FCC (%)</th>
<th>Polyox WSR 301 (%)</th>
<th>Methocel K100 (%)</th>
<th>Citric acid (%)</th>
<th>Lubritab (%)</th>
<th>Caffeine (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF1 (hydrophilic)</td>
<td>56.25</td>
<td>7.50</td>
<td>10.875</td>
<td>0.375</td>
<td>0.00</td>
<td>25.00</td>
</tr>
<tr>
<td>LF2 (lipophilic)</td>
<td>37.50</td>
<td>5.00</td>
<td>0.000</td>
<td>0.000</td>
<td>40.83</td>
<td>16.67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>No Floating lag time</th>
<th>Formulation HF1 (hydrophilic)</th>
<th>Formulation LF2 (lipophilic)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Floating behavior</td>
<td>Tablets eroded completely while releasing drug substance</td>
<td>Lipophilic matrix remained after complete drug release</td>
</tr>
<tr>
<td>Floating time</td>
<td>90 min</td>
<td>Several days</td>
</tr>
<tr>
<td>Drug release</td>
<td>100% caffeine released after 90 min</td>
<td>100% caffeine released after 17 h</td>
</tr>
<tr>
<td>Drug release mechanism</td>
<td>Erosion controlled</td>
<td>Diffusion controlled</td>
</tr>
</tbody>
</table>
Our Technical Services and Innovation Department can assist you in finding the optimal formulation with Omyapharm FCC and your API.
Omya has taken every possible care to ensure that the information herein is correct in all aspects. However, Omya cannot be held responsible for any errors or omissions which may be found herein, nor will it accept responsibility for any use which may be of the information, the same having been given in good faith, but without legal responsibility. This information does not give rise to any warranties of any kind, expressed or implied, including fitness for purpose and non-infringement of intellectual property. The technical information presented comprises typical data and should not be taken as representing a specification. Omya reserves the right to change any of the data without notice.

Contact:
Dr. Michael Skovby
Phone: +41 62 789 2260
Mail: Michael.Skovby@omya.com